Duffy D M, Stewart D R, Stouffer R L
Division of Reproductive Sciences, Oregon Regional Primate Research Center, Beaverton 97006, USA.
J Clin Endocrinol Metab. 1999 Jan;84(1):342-9. doi: 10.1210/jcem.84.1.5362.
These studies were designed to identify 1) a regimen of a third generation GnRH antagonist that abolishes primate luteal function, and 2) the amount of LH replacement required to maintain the structure and functional life span of the corpus luteum of the menstrual cycle after GnRH antagonist treatment. A single injection of antide at 3 or 5 mg/kg BW on day 6 of the luteal phase suppressed serum progesterone levels within 1 day of treatment, but levels recovered within 4 days. Administration of antide (3 mg/kg) for 3 days (luteal days 6-8) reduced (P < 0.05) serum progesterone below 1 ng/mL and maintained these low levels for the entire sampling period; in subsequent experiments, all monkeys received this antide regimen. Fixed doses (5, 10, or 20 IU) of recombinant human LH administered at 8-h intervals during and after antide treatment stimulated progesterone production in a dose-dependent manner; these monkeys menstruated earlier than controls regardless of treatment group. Replacement with an escalating dose regimen (5-20 IU) of LH resulted in typical serum progesterone and relaxin levels throughout a luteal phase of normal length. Corpora lutea removed on day 10 from monkeys treated with antide alone had decreased wet weight (P < 0.05) and few large luteal cells; coadministration of the escalating dose regimen of LH maintained luteal structure similar to that seen in time-matched controls. Antide-only treatment increased progesterone receptor (PR) messenger ribonucleic acid, but decreased PR immunostaining in luteal tissue; the escalating dose regimen of LH maintained PR messenger ribonucleic acid and immunostaining similar to those in controls. This study indicates that during GnRH antagonist administration, an escalating dose regimen of LH replacement is optimal for maintenance of the structure and functional life span of the primate corpus luteum.
1)一种能消除灵长类动物黄体功能的第三代促性腺激素释放激素(GnRH)拮抗剂方案;2)在GnRH拮抗剂治疗后,维持月经周期黄体结构和功能寿命所需的促黄体生成素(LH)替代量。在黄体期第6天单次注射3或5mg/kg体重的安替肽,在治疗后1天内可抑制血清孕酮水平,但4天内水平恢复。在黄体期第6 - 8天连续3天给予安替肽(3mg/kg)可使血清孕酮水平降低(P < 0.05)至1ng/mL以下,并在整个采样期维持低水平;在后续实验中,所有猴子均接受此安替肽方案。在安替肽治疗期间及之后,每隔8小时给予固定剂量(5、10或20IU)的重组人LH,可剂量依赖性地刺激孕酮生成;无论治疗组如何,这些猴子比对照组更早月经来潮。用递增剂量方案(5 - 20IU)的LH替代可在正常长度的黄体期内产生典型的血清孕酮和松弛素水平。在第10天从仅接受安替肽治疗的猴子身上取出的黄体,其湿重降低(P < 0.05)且大黄体细胞较少;同时给予递增剂量方案的LH可维持黄体结构,类似于同期对照。仅用安替肽治疗可增加黄体组织中孕酮受体(PR)信使核糖核酸,但降低PR免疫染色;递增剂量方案的LH可维持PR信使核糖核酸和免疫染色,类似于对照组。本研究表明,在给予GnRH拮抗剂期间,递增剂量方案的LH替代对于维持灵长类动物黄体的结构和功能寿命是最佳的。